Sana BiotechnologySANA
SANA
About: Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
Employees: 194
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more call options, than puts
Call options by funds: $1.07M | Put options by funds: $712K
32% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 41
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
3% less capital invested
Capital invested by funds: $258M [Q4 2024] → $252M (-$6.85M) [Q1 2025]
6% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 32
2% less funds holding
Funds holding: 164 [Q4 2024] → 161 (-3) [Q1 2025]
4.47% less ownership
Funds ownership: 70.78% [Q4 2024] → 66.32% (-4.47%) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
20%
upside
Avg. target
$9.33
123%
upside
High target
$12
187%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Morgan Stanley Maxwell Skor | 187%upside $12 | Overweight Assumed | 3 Jul 2025 |
JMP Securities Reni Benjamin | 20%upside $5 | Market Outperform Reiterated | 24 Jun 2025 |
HC Wainwright & Co. Emily Bodnar | 163%upside $11 | Buy Reiterated | 24 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression
Neutral
Benzinga
2 weeks ago
Two Biotech Stocks Poised For Big Moves On Monday
Two Biotechs Poised For Big Moves On Monday (Sana Biotechnology | Lineage Cell Therapeutics)
Neutral
GlobeNewsWire
1 month ago
Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions
Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes
Neutral
GlobeNewsWire
1 month ago
Sana Biotechnology to Present at June 2025 Investor Conferences
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update.
Neutral
Accesswire
1 month ago
Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149443&wire=1&utm_campaign=3 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
1 month ago
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or “the Company”) (NASDAQ: SANA) and certain of its officers.
Neutral
Accesswire
1 month ago
Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Before May 20, 2025 - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149393&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
1 month ago
SANA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ:SANA) between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
NEW YORK , May 20, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
Neutral
Accesswire
1 month ago
Lost Money on Sana Biotechnology, Inc. (SANA)? Contact Levi & Korsinsky to Join Class Action Before May 20, 2025
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149338&wire=1&utm_campaign=20 or contact Joseph E. Levi, Esq.
Charts implemented using Lightweight Charts™